MedTrace Logo

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2025-07-29

Study results available
· View outcomes & findings →

Summary

This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response.

This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

Conditions

  • Solid Tumor, Adult

Interventions

COMBINATION_PRODUCT

TTX-030, budigalimab and mFOLFOX6

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030, budigalimab and docetaxel

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030 and mFOLFOX6

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030 and budigalimab

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030, budigalimab, nab-paclitaxel and gemcitabine

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030 and pembrolizumab

Dose and schedule per protocol

COMBINATION_PRODUCT

TTX-030, nab-paclitaxel and gemcitabine

Dose and schedule per protocol

COMBINATION_PRODUCT

Budigalimab and mFOLFOX6

Dose and schedule per protocol

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Trishula Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2022-11-30
Completion
2024-03-27
FDA Drug
Yes

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04306900 on ClinicalTrials.gov